Marksans PharmaBOM:524404 +0.94%86 Interest Coverage is 27.12 as of Mar. 2026, which is 20% below its 10-year median of 33.97. GuruFocus rates BOM:524404 with a GF Score™ of 86/100 and a GF Value™ of ₹228.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, Marksans Pharma ranks better than 59.56% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Marksans Pharma's
Operating Income
for the
three
months ended in Mar. 2026 was ₹1,711 Mil. Marksans Pharma's Interest Expense for the
three
months ended in Mar. 2026 was ₹-63 Mil.
Marksans Pharma's interest coverage for the quarter that ended in Mar. 2026 was 27.12.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Marksans Pharma's Interest Coverage or its related term are showing as below:
BOM:524404'
s Interest Coverage Range Over the Past 10 Years
Min: 0.71 Med: 33.97 Max: 91.93
Current: 20.81
BOM:524404's Interest Coverage is ranked better than 59.56% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:524404: 20.81
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Marksans Pharma Interest Coverage Related Terms
Marksans Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Marksans Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:524404 vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marksans Pharma (BOM:524404) has a Interest Coverage of 27.12 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Marksans Pharma and its competitors. This is 20% below median its historical median of 33.97. Over the past decade, Marksans Pharma's Interest Coverage has ranged from 0.71 to 91.93. According to the industry distribution chart, Marksans Pharma ranks #277 out of 685 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is Marksans Pharma's Interest Coverage too high?
Marksans Pharma's current Interest Coverage of 27.12 is 20% below median its 10-year median of 33.97. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 91.93. The Drug Manufacturers industry median Interest Coverage is 12.75. Marksans Pharma's value of 27.12 is 112.7% above this industry median. Based on the distribution chart, Marksans Pharma ranks #277 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Marksans Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Marksans Pharma ranks #277 out of 685 companies for Interest Coverage. This puts Marksans Pharma in the upper half of its industry. The industry median Interest Coverage is 12.75. Marksans Pharma's value of 27.12 is 112.7% above this benchmark. Historically, Marksans Pharma's own Interest Coverage has ranged from 0.71 to 91.93 over the past decade. While the company's 10-year median is 33.97 vs. the industry median of 12.75, Marksans Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marksans Pharma's current Interest Coverage of 27.12 is 112.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Marksans Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marksans Pharma's current Interest Coverage is 27.12, which is 20% below median its own 10-year median of 33.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹228.54, compared to a current price of ₹263.50 — trading 15.3% above its estimated fair value. The current Interest Coverage is 27.12, which is 20% below median its 10-year median of 33.97 and 112.7% above the Drug Manufacturers industry median of 12.75. Marksans Pharma's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Interest Coverage is 27.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹263.50 is trading 15.3% above its estimated GF Value™ of ₹228.54.
GuruFocus considers Marksans Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524404:
Interest Coverage: 27.12 (20% below median its 10-year median of 33.97)
GF Value™: ₹228.54 vs. price of ₹263.50 (15.3% above fair value)
Industry Position: 112.7% above the Drug Manufacturers median (#277 of 685)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
86GF Score
Get the complete analysis for BOM:524404
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
